查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1968562

多核苷酸注射市场－全球产业规模、份额、趋势、机会、预测：按应用、最终用途、地区和竞争格局划分，2021-2031年

Polynucleotides Injectable Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球多核苷酸注射剂市场预计将从 2025 年的 1.3612 亿美元成长到 2031 年的 2.3736 亿美元，复合年增长率为 9.71%。

该市场以生物刺激剂产品为特征，这些产品通常含有源自鲑鱼或鳟鱼的超高纯度DNA片段。注射这些产品可活化纤维母细胞，促进生理性组织再生、保湿和胶原蛋白生成，而无需人为增加皮肤容量。推动这一市场成长的主要动力是消费者偏好的显着转变，他们开始追求再生美容和自然美观的效果。与传统填充剂带来的即时容量提升相比，患者越来越重视改善肤质和修復细胞。

市场概览
预测期 2027-2031
市场规模：2025年 1.3612亿美元
市场规模：2031年 2.3736亿美元
复合年增长率：2026-2031年 9.71%
成长最快的细分市场 眼科
最大的市场 北美洲

然而，由于法规环境分散，市场面临许多挑战。从医疗设备到药品，不同司法管辖区之间缺乏统一的产品分类，阻碍了全球标准化和核准。儘管存在这些监管挑战，专业人士对该技术的接受度仍然很高。根据韩国美容整形外科学会和韩国雷射医学会的调查，2024年接受调查的整形外科医生中，75.7%的人表示使用多核苷酸注射治疗因皮脂分泌过多引起的毛孔粗大，这表明此类治疗方法在临床实践中正在迅速普及。

市场驱动因素

市场扩张的主要驱动力是全球对微创抗衰老治疗日益增长的需求。患者越来越倾向于选择能够改善皮肤结构、带来自然效果且恢復期短的治疗方案，而非传统填充剂带来的即时丰盈效果。非侵入性治疗数量的激增也印证了这项转变。根据国际美容整形外科学会 (ISAPS) 于 2024 年 6 月发布的《全球美容整形外科手术调查报告》，2023 年全球共进行了 1,910 万例非手术治疗，显示针刺治疗方法的需求持续旺盛。多核苷酸正是顺应了这个趋势，透过促进生理修復过程，从内而外增强皮肤弹性和水润度，满足了消费者对再生医学解决方案的需求。

同时，多核苷酸注射剂在生髮和脱髮症治疗领域的应用不断拓展，也扩大了其潜在市场。这些注射因能促进微循环和刺激毛囊细胞增殖，有效治疗男性型脱髮症（雄性脱毛症）而广受欢迎。临床数据也支持其疗效；2024年发表于《皮肤病学研究檔案》（Archives of Dermatological Research）的一项研究报告称，接受多核苷酸注射的患者中，77.8%在18週后出现轻度至中度的毛髮再生。该治疗方法的广泛应用也促使更多医疗专业人员采用；2024年发表于《美容皮肤病学杂誌》（Journal of Cosmetic Dermatology）的一项调查显示，韩国88%的註册皮肤科医生已将多核苷酸注射纳入其临床实践。

市场挑战

全球多核苷酸注射剂市场面临的主要障碍是监管环境的碎片化。这为製造商设置了复杂且成本高昂的进入门槛。由于不同地区的药品分类不一致（多核苷酸在某些地区被归类为医疗设备，而在其他地区则被归类为药品），企业必须应对不同的核准流程。这种缺乏协调性导致企业需要在每个司法管辖区分别开展耗资巨大的临床试验和製定合规策略，从而显着延迟产品上市，并限制了这些注射剂的全球供应。

这种监管瓶颈直接阻碍了市场扩张，因为它无法满足专业人士对再生美容医学日益增长的需求。例如，美国脸部整形与重组外科学会（AAFPRS）在2024年报告称，57%的脸部整形外科医师认为再生医学是一个重要的创新领域。儘管有明确证据表明市场已经成熟，且医疗专业人士的需求旺盛，但监管摩擦限制了这些专业人士可获得的已通过核准的多核苷酸产品，人为地限制了市场潜力，并阻碍了其像在其他更标准化的美容领域那样得到广泛应用。

市场趋势

年轻一代对「预防性抗衰老」策略的兴起，正迅速改变全球多核苷酸注射市场的患者获取模式。年轻消费者，尤其是千禧世代和Z世代，越来越多地使用这些生物刺激剂，并非为了修復肌肤问题，而是作为预防措施，以维持肌肤品质并延缓老化迹象。他们被多核苷酸的特性所吸引，这些特性能够改善肌肤水润度和质地，而不会像传统填充剂那样造成结构性改变，符合所谓「玻璃肌」的美学理想。这种兴趣的激增是可以量化的；根据DermaFocus在2024年12月进行的一项调查，与上个月相比，多核苷酸的网路搜寻激增了2446%。这主要是由于患者寻求名人推荐的护肤方案以达到预防老化的目的。

第二个显着的趋势是，多核苷酸注射疗法在男性美容和护理领域的应用日益广泛，这也扩大了该疗法的治疗范围。男性患者选择多核苷酸注射疗法，因为它能够活化肌肤，提升弹性，且不会像人工填充那样导致脸部特征女性化。这符合男性追求「隐藏式治疗」的偏好，他们希望在解决痤疮疤痕、偏好粗糙等特定问题的同时，保持男性化的骨骼结构。专业的临床数据也支持这项转变。英国美容医学会 (BCAM) 于 2024 年 9 月发布的《BCAM 2024 年度临床回顾》显示，其会员医生治疗的所有患者中，男性占 16%，这表明这些生物再生通讯协定正逐渐成为男性日常美容护理的一部分。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球多核苷酸注射剂市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依应用部位（眼部、唇部、额头、下颚线/颧骨等）
    • 依最终用途（医疗水疗中心、美容/整形中心、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美多核苷酸注射剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲多核苷酸注射剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区多核苷酸注射剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲多核苷酸注射剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲多核苷酸注射剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球多核苷酸注射剂市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • PharmaResearch
  • Bioplus Co., Ltd.
  • AMEELA
  • Mastelli Srl
  • MD Skin Solutions
  • Fox Pharma Ltd
  • BRPHARM Co., Ltd.
  • DermaFocus Ltd
  • ADM Skin Clinic
  • The Doctor & Company

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 27472

The Global Polynucleotides Injectable Market is projected to expand from USD 136.12 Million in 2025 to USD 237.36 Million by 2031, reflecting a CAGR of 9.71%. This market is characterized by biostimulatory products comprising ultra-pure DNA fractions, usually sourced from salmon or trout, which are injected to stimulate fibroblasts and encourage physiological tissue regeneration, hydration, and collagen production without adding artificial volume. The primary force driving this growth is a significant shift in consumer preference toward regenerative aesthetics and natural-looking outcomes, as patients increasingly value skin quality enhancement and cellular repair over the immediate volume correction associated with traditional fillers.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 136.12 MIllion
Market Size 2031USD 237.36 MIllion
CAGR 2026-20319.71%
Fastest Growing SegmentEyes
Largest MarketNorth America

However, the market faces a substantial obstacle due to a fragmented regulatory environment, where inconsistent product classifications-ranging from medical devices to pharmaceuticals across various jurisdictions-create hurdles for global standardization and approval. Despite these regulatory challenges, professional adoption remains robust; according to the Korean Aesthetic Surgery and Laser Society, 75.7% of cosmetic physicians surveyed in 2024 reported using polynucleotide injections to treat enlarged facial pores resulting from excessive sebum production, highlighting the rapid uptake of these therapies in clinical practice.

Market Driver

The expansion of the market is largely fueled by surging global demand for minimally invasive anti-aging procedures, with patients increasingly prioritizing treatments that offer structural improvements and natural results with minimal downtime, rather than the immediate volume enhancement of traditional fillers. This shift is highlighted by the sheer volume of non-invasive treatments; the International Society of Aesthetic Plastic Surgery reported in its June 2024 'Global Survey on Aesthetic/Cosmetic Procedures' that 19.1 million non-surgical procedures were conducted worldwide in 2023, indicating a persistent appetite for needle-based therapies. Polynucleotides leverage this trend by triggering physiological repair processes that enhance skin elasticity and hydration from within, satisfying the consumer desire for regenerative solutions.

Simultaneously, the market's addressable scope is widening through growing applications in hair restoration and alopecia treatment. These injectables are gaining popularity for androgenetic alopecia by boosting microcirculation and stimulating follicle cell proliferation. Clinical data supports this efficacy; a study published in the Archives of Dermatological Research in 2024 noted that 77.8% of patients treated with polynucleotide injections experienced slight to moderate hair regrowth after 18 weeks. This therapeutic versatility has driven high adoption rates among practitioners, with a survey in the Journal of Cosmetic Dermatology in April 2024 revealing that 88% of board-certified dermatologists in South Korea have incorporated polynucleotide injections into their practice.

Market Challenge

A major factor hindering the Global Polynucleotides Injectable Market is the fragmented regulatory landscape, which imposes complex and costly barriers to entry for manufacturers. Because product classifications are inconsistent-with polynucleotides categorized as medical devices in some regions and pharmaceuticals in others-companies must navigate divergent approval pathways. This lack of harmonization requires the execution of separate, capital-intensive clinical trials and compliance strategies for each jurisdiction, significantly delaying product launches and restricting the global availability of these injectables.

This regulatory bottleneck directly stifles market expansion by preventing supply from meeting the rapidly rising professional interest in regenerative aesthetics. For instance, the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) reported in 2024 that 57% of facial plastic surgeons consider regenerative medicine a major area of innovation. Despite this clear evidence of market readiness and high practitioner demand, regulatory friction limits the number of approved polynucleotide products available to these professionals, artificially capping the market's potential and preventing these therapies from achieving the widespread adoption rates seen in more standardized aesthetic categories.

Market Trends

The rise of pre-juvenation strategies among younger demographics is rapidly shifting patient acquisition patterns within the Global Polynucleotides Injectable Market. Younger consumers, specifically Millennials and Gen Z, are increasingly using these biostimulators as a preventative measure to maintain skin quality and delay aging signs rather than for correction. This demographic is attracted to the ability of polynucleotides to improve hydration and texture without the structural changes associated with traditional fillers, aligning with the "glass skin" aesthetic. This surge in interest is quantifiable; according to DermaFocus in December 2024, internet searches for polynucleotides increased by a dramatic 2,446% over the preceding months, driven largely by patients seeking these preventative, celebrity-endorsed skin regimens.

A second pivotal trend expanding the therapy's scope is its increasing utilization in male grooming and aesthetic regimens. Male patients are gravitating toward polynucleotide injections because they offer skin revitalization and improved elasticity without adding artificial volume, which can inadvertently feminize facial features. This aligns with the male preference for undetectable treatments that maintain masculine structural definition while addressing specific issues like acne scarring or coarse texture. Professional clinical data supports this shift; the British College of Aesthetic Medicine's September 2024 'BCAM 2024 Annual Clinical Review' noted that 16% of all patients treated by member physicians were male, indicating the sustained integration of these bio-regenerative protocols into men's aesthetic maintenance routines.

Key Market Players

  • PharmaResearch
  • Bioplus Co., Ltd.
  • AMEELA
  • Mastelli Srl
  • MD Skin Solutions
  • Fox Pharma Ltd
  • BRPHARM Co., Ltd.
  • DermaFocus Ltd
  • ADM Skin Clinic
  • The Doctor & Company

Report Scope

In this report, the Global Polynucleotides Injectable Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Polynucleotides Injectable Market, By Application

  • Eyes
  • Lips
  • Forehead
  • Jawline & Cheekbones
  • Others

Polynucleotides Injectable Market, By End Use

  • Med Spas
  • Aesthetic & Cosmetic Centers
  • Others

Polynucleotides Injectable Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Polynucleotides Injectable Market.

Available Customizations:

Global Polynucleotides Injectable Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Polynucleotides Injectable Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Eyes, Lips, Forehead, Jawline & Cheekbones, Others)
    • 5.2.2. By End Use (Med Spas, Aesthetic & Cosmetic Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Polynucleotides Injectable Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Polynucleotides Injectable Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Polynucleotides Injectable Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Polynucleotides Injectable Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By End Use

7. Europe Polynucleotides Injectable Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Polynucleotides Injectable Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Polynucleotides Injectable Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Polynucleotides Injectable Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Polynucleotides Injectable Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Polynucleotides Injectable Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By End Use

8. Asia Pacific Polynucleotides Injectable Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Polynucleotides Injectable Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Polynucleotides Injectable Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Polynucleotides Injectable Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Polynucleotides Injectable Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Polynucleotides Injectable Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Polynucleotides Injectable Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Polynucleotides Injectable Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Polynucleotides Injectable Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Polynucleotides Injectable Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By End Use

10. South America Polynucleotides Injectable Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Polynucleotides Injectable Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Polynucleotides Injectable Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Polynucleotides Injectable Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Polynucleotides Injectable Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. PharmaResearch
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bioplus Co., Ltd.
  • 15.3. AMEELA
  • 15.4. Mastelli Srl
  • 15.5. MD Skin Solutions
  • 15.6. Fox Pharma Ltd
  • 15.7. BRPHARM Co., Ltd.
  • 15.8. DermaFocus Ltd
  • 15.9. ADM Skin Clinic
  • 15.10. The Doctor & Company

16. Strategic Recommendations

17. About Us & Disclaimer